Latest & greatest articles for pregabalin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pregabalin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pregabalin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pregabalin

25. Double-blind, randomized, controlled, crossover trial of pregabalin for neurogenic claudication

Double-blind, randomized, controlled, crossover trial of pregabalin for neurogenic claudication 25503625 2015 01 20 2015 05 04 2016 12 15 1526-632X 84 3 2015 Jan 20 Neurology Neurology Double-blind, randomized, controlled, crossover trial of pregabalin for neurogenic claudication. 265-72 10.1212/WNL.0000000000001168 To test the effects of pregabalin on the induction of neurogenic claudication. This study was a randomized, double-blind, active placebo-controlled, 2-period, crossover trial (...) . Twenty-nine subjects were randomized to receive pregabalin followed by active placebo (i.e., diphenhydramine) or active placebo followed by pregabalin. Each treatment period lasted 10 days, including a 2-step titration. Periods were separated by a 10-day washout period, including a 3-day taper phase after the first period. The primary outcome variable was the time to first moderate pain symptom (Numeric Rating Scale score ≥4) during a 15-minute treadmill test (Tfirst). Secondary outcome measures

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

26. Gabapentin and pregabalin: major adverse effects

Gabapentin and pregabalin: major adverse effects Prescrire IN ENGLISH - Spotlight ''Gabapentin and pregabalin: major adverse effects'', 1 November 2014 {1} {1} {1} | | > > > Gabapentin and pregabalin: major adverse effects Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Gabapentin and pregabalin: major adverse effects To reduce the consequences (...) of some severe adverse effects associated with gabapentin or pregabalin, it is advisable not to expose patients to them other than in situations where these drugs have proved to be highly effective. Gabapentin and pregabalin are used in certain epilepsies and for pain in neurological diseases. Pregabalin is also used to treat anxiety disorders. According to a review of French pharmacovigilance data published in 2013, between 1995 and 2009, 2415 adverse effects linked to gabapentin or pregabalin were

Prescrire2014

27. Comparison of pregabalin with pramipexole for restless legs syndrome.

Comparison of pregabalin with pramipexole for restless legs syndrome. BACKGROUND: Dopaminergic medications relieve symptoms of the restless legs syndrome (RLS) but have the potential to cause iatrogenic worsening (augmentation) of RLS with long-term treatment. Pregabalin may be an effective alternative. METHODS: In this 52-week, randomized, double-blind trial, we assessed efficacy and augmentation in patients with RLS who were treated with pregabalin as compared with placebo and pramipexole (...) . Patients were randomly assigned to receive 52 weeks of treatment with pregabalin at a dose of 300 mg per day or pramipexole at a dose of 0.25 mg or 0.5 mg per day or 12 weeks of placebo followed by 40 weeks of randomly assigned active treatment. The primary analyses involved a comparison of pregabalin and placebo over a period of 12 weeks with use of the International RLS (IRLS) Study Group Rating Scale (on which the score ranges from 0 to 40, with a higher score indicating more severe symptoms

NEJM2014

28. Pregabalin

Pregabalin USE OF PREGABALIN IN PREGNANCY 0344 892 0909 USE OF PREGABALIN IN PREGNANCY (Date of issue: June 2016 , Version: 3.1 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Pregabalin is an anticonvulsant used as adjunctive therapy in adults (...) with partial seizures, with or without secondary generalisation, and in the treatment of neuropathic pain and generalised anxiety disorder. There is limited information on the use of pregabalin in pregnancy, with less than 200 exposures in the published literature. Fetal toxicity has been reported in animal studies. A prospective cohort study found a significant increased risk of major malformation in comparison with unexposed controls, however these findings are limited by the small number of exposed

UK Teratology Information Service2014

30. Pregabalin in Patients With Inadequately Treated Painful Diabetic Peripheral Neuropathy: A Randomized Withdrawal Trial

Pregabalin in Patients With Inadequately Treated Painful Diabetic Peripheral Neuropathy: A Randomized Withdrawal Trial 23887339 2014 04 08 2014 11 26 2015 11 19 1536-5409 30 5 2014 May The Clinical journal of pain Clin J Pain Pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy: a randomized withdrawal trial. 379-90 10.1097/AJP.0b013e31829ea1a1 This study used a randomized withdrawal design to evaluate the efficacy of pregabalin versus placebo for pain (...) relief in patients with painful diabetic peripheral neuropathy inadequately treated by other therapies. A total of 665 patients received pregabalin in a 6-week single-blind phase. Two hundred ninety-four patients who achieved a ≥ 30% pain response were randomized to receive pregabalin or placebo in a double-blind phase for a further 13 weeks. The primary endpoint was the change in mean pain score from single-blind baseline to double-blind endpoint for pregabalin versus placebo (last observation carried forward

EvidenceUpdates2013

31. Combination of Pregabalin and Dexamethasone for Postoperative Pain and Functional Outcome in Patients Undergoing Lumbar Spinal Surgery: A Randomized Placebo-controlled Trial

Combination of Pregabalin and Dexamethasone for Postoperative Pain and Functional Outcome in Patients Undergoing Lumbar Spinal Surgery: A Randomized Placebo-controlled Trial 22751028 2012 12 05 2013 06 05 2015 11 19 1536-5409 29 1 2013 Jan The Clinical journal of pain Clin J Pain Combination of pregabalin and dexamethasone for postoperative pain and functional outcome in patients undergoing lumbar spinal surgery: a randomized placebo-controlled trial. 9-14 10.1097/AJP.0b013e318246d1a9 (...) In this randomized-controlled study, we investigated the effects of combined administration of pregabalin and dexamethasone on postoperative pain and analgesic requirements, and functional outcome in patients who underwent lumbar spinal surgery. One hundred eight patients were randomized to group C (placebo+placebo), group P (pregabalin + placebo), or group PD (pregabalin+dexamethasone). According to their allocated group, patients received placebo or pregabalin 150 mg every 12 hours starting 1 hour before

EvidenceUpdates2013

32. Abuse and misuse potential of pregabalin: a review of the clinical evidence

Abuse and misuse potential of pregabalin: a review of the clinical evidence Abuse and misuse potential of pregabalin: a review of the clinical evidence Abuse and misuse potential of pregabalin: a review of the clinical evidence CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Abuse and misuse potential of pregabalin: a review (...) of the clinical evidence. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions There is a limited volume of evidence regarding the abuse and misuse potential of pregabalin. Existing evidence is generally of low quality and suggests that certain populations with a history of substance abuse may be at increased risk to abuse pregabalin. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Analgesics; Anticonvulsants; Drug and Narcotic Controls

Health Technology Assessment (HTA) Database.2012

33. A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain

A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain Gordon J, Lister S, Prettyjohns M, McEwan P, Tetlow A, Gabriel Z Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of pregabalin for patients with refractory neuropathic pain. The authors concluded that it was a cost-effective alternative to usual care. On the whole, the methods were well reported and the authors' conclusions seem valid for pregabalin in addition to usual care, rather than as an alternative. Type of economic

NHS Economic Evaluation Database.2012

34. The cost-effectiveness of pregabalin in the treatment of fibromyalgia: US perspective

The cost-effectiveness of pregabalin in the treatment of fibromyalgia: US perspective The cost-effectiveness of pregabalin in the treatment of fibromyalgia: US perspective The cost-effectiveness of pregabalin in the treatment of fibromyalgia: US perspective Lloyd A, Boomershine CS, Choy EH, Chandran A, Zlateva G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined the cost-effectiveness of pregabalin for treatment of severe fibromyalgia compared with placebo, duloxetine, milnacipran, gabapentin, tramadol and amitriptyline. The authors concluded that pregabalin was more beneficial and less expensive than the other available treatments for severe fibromyalgia, except when compared to amitriptyline. The study used valid

NHS Economic Evaluation Database.2012

35. Pregabalin for chronic prostatitis.

Pregabalin for chronic prostatitis. BACKGROUND: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a condition that is detrimental to the quality of life of men. Evidence suggests that it may have a neuropathic origin and therefore medications such as pregabalin might have a role in the controlling of symptoms. OBJECTIVES: The primary objective was to compare pregabalin to other modalities of pain relief to alleviate men's symptoms of CP/CPPS.The secondary objective was to assess (...) the safety and effectiveness of pregabalin to improve various individual symptoms consistent with CP/CPPS. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1966 to May 2012), EMBASE (1980 to May 2012), CINAHL, clinicaltrials.gov, Google Scholar, and reference lists of articles and abstracts from conference proceedings, without language restriction for pregabalin treatment of Class III prostatitis and CP/CPPS. SELECTION CRITERIA: Randomized controlled

Cochrane2012

36. Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover polysomnography study

Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover polysomnography study 22232085 2012 03 29 2012 07 02 2015 11 19 2151-4658 64 4 2012 Apr Arthritis care & research Arthritis Care Res (Hoboken) Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover polysomnography study. 597-606 10.1002/acr.21595 To assess (...) the effect of pregabalin on polysomnographic (PSG) measures of sleep and patient-rated sleep, tiredness, and pain in fibromyalgia patients. We performed a randomized, double-blind, placebo-controlled, 2-period crossover PSG study. Patients ages ≥18 years with fibromyalgia satisfied subjective and objective sleep disturbance criteria prior to randomization. Eligible patients were randomized (1:1) to pregabalin (300-450 mg/day) or placebo for crossover period 1, and vice versa for period 2. Each crossover

EvidenceUpdates2012

37. Pregabalin oral solution (Lyrica) - for the treatment of peripheral and central neuropathic pain in adults

Pregabalin oral solution (Lyrica) - for the treatment of peripheral and central neuropathic pain in adults

Scottish Medicines Consortium2012

39. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials

The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials Zaccara G, Gangemi P, Perucca P, Specchio L CRD summary The review concluded that individuals starting pregabalin treatment were at increased risk of several adverse (...) events, particularly those affecting cognition/co-ordination, which followed a dose-response relationship. The review was generally well conducted, but the potential issues with trial quality and the small number of trials for some adverse events limit the reliability of the results. Authors' objectives To determine the adverse event profile of pregabalin. Searching MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched to February 2010. Search terms were

DARE.2012

40. Can pregabalin effectively diminish acute herpetic pain and reduce the incidence of post-herpetic neuralgia in patients who present with acute herpes zoster?

Can pregabalin effectively diminish acute herpetic pain and reduce the incidence of post-herpetic neuralgia in patients who present with acute herpes zoster? BestBets: Can pregabalin effectively diminish acute herpetic pain and reduce the incidence of post-herpetic neuralgia in patients who present with acute herpes zoster? Can pregabalin effectively diminish acute herpetic pain and reduce the incidence of post-herpetic neuralgia in patients who present with acute herpes zoster? Report (...) By: Eliane Raymond-Dufresne - PGY-3, Emergency Medicine Search checked by Katharine Wylie - Senior Informatacist Institution: Laval University, Qu�bec, Canada Date Submitted: 23rd November 2011 Date Completed: 13th February 2012 Last Modified: 20th February 2012 Status: Green (complete) Three Part Question In [patients with new onset of herpes zoster infection], can [pregabalin] be used to [decrease the incidence of post-herpetic neuralgia and to decrease the intensity of acute herpetic pain]? Clinical

BestBETS2012